Bristol, Ambrx team up to develop antibody-based cancer drugs

05/6/2013 | Genetic Engineering & Biotechnology News

Bristol-Myers Squibb and Ambrx agreed to co-develop antibody drug conjugates for cancer with the latter's protein medicinal technology. Ambrx will receive $15 million upfront and as much as $97 million in research funding and milestone fees for each product, plus sales royalties. Bristol will get the global rights to develop and market the drugs arising from the partnership.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA